Logo image
Back
Pharmacology and Pharmacokinetics of Minoxidil
Journal article   Peer reviewed

Pharmacology and Pharmacokinetics of Minoxidil

David Lowenthal and Melton Affrime
Journal of cardiovascular pharmacology, v 2 Suppl 2, pp S93-106
1980
DOI: https://doi.org/10.1097/00005344-198000022-00002
PMID: 6156363
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Minoxidil is a potent oral vasodilator acting on the arteriolar side of the circulation. Reflex tachycardia and sodium retention are consequences of increased sympathetic activity. Its biotransformation is 90% hepatic, with no evidence of accumulation of minoxidil when it is given chronically in patients with either normal or abnormal renal function. The half-life is approximately 3 hr, regardless of whether the dose is given singly or on a multiple-dose basis. It is widely distributed throughout the body, and hence its volume of distribution is greater than 200 liters. There appears to be a dissociation between the peak plasma concentration and the antihypertensive response owing to the fact that minoxidil rapidly leaves the plasma on its way to the principal site of action, that is, the vascular smooth-muscle receptor site. No tolerance or refractoriness appears to develop with long-term minoxidil administration.

Metrics

1 Record Views
65 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Pharmacology & Pharmacy
Logo image